Deric L Wheeler

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. pmc Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck
    Hanneke Stegeman
    Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    BMC Cancer 12:463. 2012
  2. pmc The role of Src in solid tumors
    Deric L Wheeler
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Oncologist 14:667-78. 2009
  3. pmc Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab
    Deric L Wheeler
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Cancer Biol Ther 8:696-703. 2009
  4. pmc Understanding resistance to EGFR inhibitors-impact on future treatment strategies
    Deric L Wheeler
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI 53705, USA
    Nat Rev Clin Oncol 7:493-507. 2010
  5. pmc Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells
    Sergio Benavente
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792 0600, USA
    Clin Cancer Res 15:1585-92. 2009
  6. pmc Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors
    Tim J Kruser
    Department of Human Oncology, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Clin Cancer Res 16:3639-47. 2010
  7. pmc Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Semin Radiat Oncol 19:63-8. 2009
  8. pmc Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer
    Tim J Kruser
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Int J Radiat Oncol Biol Phys 72:534-42. 2008
  9. pmc Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab
    Toni M Brand
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI USA
    Cancer Biol Ther 12:436-46. 2011
  10. pmc p53 modulates acquired resistance to EGFR inhibitors and radiation
    Shyhmin Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
    Cancer Res 71:7071-9. 2011

Collaborators

Detail Information

Publications30

  1. pmc Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck
    Hanneke Stegeman
    Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    BMC Cancer 12:463. 2012
    ..As hypoxia is an important microenvironmental parameter associated with poor outcome in solid tumors after radiotherapy, we investigated the relationship with hypoxia in vitro and in vivo...
  2. pmc The role of Src in solid tumors
    Deric L Wheeler
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Oncologist 14:667-78. 2009
    ..This review discusses the role of SFKs in solid tumors and the recent therapeutic advances aimed at targeting this family of tyrosine kinases in cancer...
  3. pmc Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab
    Deric L Wheeler
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Cancer Biol Ther 8:696-703. 2009
    ....
  4. pmc Understanding resistance to EGFR inhibitors-impact on future treatment strategies
    Deric L Wheeler
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI 53705, USA
    Nat Rev Clin Oncol 7:493-507. 2010
    ..A greater understanding of the mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of cancer...
  5. pmc Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells
    Sergio Benavente
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792 0600, USA
    Clin Cancer Res 15:1585-92. 2009
    ..Many tumors, however, eventually manifest resistance to treatment. Efforts to better understand the underlying mechanisms of acquired resistance to EGFR inhibitors, and potential strategies to overcome resistance, are greatly needed...
  6. pmc Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors
    Tim J Kruser
    Department of Human Oncology, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Clin Cancer Res 16:3639-47. 2010
    ..In this report we examine the interaction between motesanib and radiation in vitro and in head and neck squamous cell carcinoma (HNSCC) xenograft models...
  7. pmc Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Semin Radiat Oncol 19:63-8. 2009
    ....
  8. pmc Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer
    Tim J Kruser
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Int J Radiat Oncol Biol Phys 72:534-42. 2008
    ..To examine the interaction between panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, and radiation in head-and-neck squamous cell carcinoma and non-small-cell lung cancer cell lines and xenografts...
  9. pmc Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab
    Toni M Brand
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI USA
    Cancer Biol Ther 12:436-46. 2011
    ....
  10. pmc p53 modulates acquired resistance to EGFR inhibitors and radiation
    Shyhmin Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
    Cancer Res 71:7071-9. 2011
    ....
  11. doi request reprint Mechanisms of resistance to HER family targeting antibodies
    Tim J Kruser
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
    Exp Cell Res 316:1083-100. 2010
    ..In this review, we discuss resistance to antibody-based therapies against the EGFR and HER2, similarities between these resistance profiles, and strategies to overcome resistance to HER family targeting monoclonal antibody therapy...
  12. pmc Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma
    Chunrong Li
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
    Radiother Oncol 97:330-7. 2010
    ..In this report we sought to determine how to block cetuximab- and radiation-induced translocation of EGFR to the nucleus in HNSCC cell lines...
  13. pmc Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab
    Mari Iida
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Wisconsin Institute for Medical Research, Madison, WI, USA
    Cancer Biol Ther 14:481-91. 2013
    ....
  14. pmc Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab
    Mari Iida
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Wisconsin Institutes for Medical Research, Madison, WI
    Neoplasia 15:1196-206. 2013
    ..These results indicate that Sym004 may be an effective targeted therapy for Ctx(R) tumors. ..
  15. ncbi request reprint Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma
    Chunrong Li
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
    Discov Med 16:79-92. 2013
    ..These findings suggest that HER3 may play an important role in response to radiation therapy and blocking its activity in combination with radiation may be of therapeutic benefit in human tumors. ..
  16. pmc The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients
    Tim J Kruser
    University of Wisconsin Comprehensive Cancer Center, Department of Human Oncology, Madison, Wisconsin, WI 53705, USA
    Expert Opin Investig Drugs 20:305-7. 2011
    ..Future studies of dasatinib in NSCLC should examine the agent in combination with EGFR inhibitors and/or cytotoxic chemotherapies...
  17. pmc Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
    Anne M Traynor
    Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Lung Cancer 81:138-41. 2013
    ..We sought to determine if protein expression of nEGFR is prognostic in early stage non-small cell lung cancer (NSCLC)...
  18. pmc Nuclear EGFR as a molecular target in cancer
    Toni M Brand
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Wisconsin Institute for Medical Research, Madison, USA
    Radiother Oncol 108:370-7. 2013
    ..In this review the current knowledge of how nuclear EGFR enhances resistance to cancer therapeutics is discussed, in addition to highlighting ways to target nuclear EGFR as an anti-cancer strategy in the future. ..
  19. pmc Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3
    Toni M Brand
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America
    PLoS ONE 8:e71518. 2013
    ..Thus, the ability for HER3 to function as a transcriptional co-activator may be dependent on specific C-terminal TADs...
  20. pmc KRAS mutant colorectal tumors: past and present
    Toni M Brand
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI USA
    Small Gtpases 3:34-9. 2012
    ....
  21. pmc Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition
    Paul A Clark
    Department of Neurological Surgery, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
    Neoplasia 14:420-8. 2012
    ....
  22. pmc The nuclear epidermal growth factor receptor signaling network and its role in cancer
    Toni M Brand
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, WIMR 3159, Madison, Wisconsin 53705, USA
    Discov Med 12:419-32. 2011
    ....
  23. pmc Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
    Toni M Brand
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Cancer Biol Ther 11:777-92. 2011
    ..Further, we provide an in depth discussion of described molecular mechanisms of resistance to cetuximab and potential strategies to circumvent this resistance...
  24. ncbi request reprint Early epidermal destruction with subsequent epidermal hyperplasia is a unique feature of the papilloma-independent squamous cell carcinoma phenotype in PKCepsilon overexpressing transgenic mice
    Yafan Li
    Molecular and Environmental Toxicology Center, University of Wisconsin, Madison, Wisconsin, USA
    Toxicol Pathol 33:684-94. 2005
    ..Prolonged hyperplasia in the hair follicle may result in the early neoplastic lesions originally described by Jansen et al. (2001) by expanding initiated cells in the hair follicles resulting in the subsequent development of SCC...
  25. ncbi request reprint Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cepsilon transgenic mice
    Deric L Wheeler
    Department of Human Oncology, Medical School, University of Wisconsin, Madison, WI 53792, USA
    Cancer Res 63:6547-55. 2003
    ....
  26. ncbi request reprint Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas
    Deric L Wheeler
    Department of Human Oncology, Medical School, University of Wisconsin, Madison, Wisconsin 53792, USA
    Cancer Res 64:7756-65. 2004
    ..Taken together, the results indicate that PKCepsilon signals UVR-induced TNFalpha release that is linked, at least in part, to the photosensitivity of PKCepsilon transgenic mice...
  27. ncbi request reprint Protein kinase Cepsilon and development of squamous cell carcinoma, the nonmelanoma human skin cancer
    Ajit K Verma
    Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin 53792, USA
    Mol Carcinog 45:381-8. 2006
    ..It appears that PKCepsilon sensitizes skin to the development of SCC by UVR by transducting signals, which inhibit apoptosis on one hand, and enhances proliferation of preneoplastic cells on the other hand...
  28. pmc Overexpression of protein kinase C-{epsilon} in the mouse epidermis leads to a spontaneous myeloproliferative-like disease
    Deric L Wheeler
    Department of Human Oncology, Medical School, University of Wisconsin, K4 532 CSC Clinical Science Center, 600 Highland Ave, Madison, WI 53792, USA
    Am J Pathol 166:117-26. 2005
    ..The susceptibility of PKC-epsilon transgenic mice to the induction of SCC and the spontaneous development of MPD are unrelated...
  29. ncbi request reprint Protein kinase C delta overexpressing transgenic mice are resistant to chemically but not to UV radiation-induced development of squamous cell carcinomas: a possible link to specific cytokines and cyclooxygenase-2
    Moammir H Aziz
    Department of Human Oncology, Medical School, University of Wisconsin, Madison, WI 53792, USA
    Cancer Res 66:713-22. 2006
    ....
  30. ncbi request reprint Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss
    Deric L Wheeler
    Department of Human Oncology, Medical School, University of Wisconsin, Madison, Wisconsin 53762, USA
    Cancer Res 63:3037-42. 2003
    ..Severe hair loss observed in PKC epsilon transgenic mice on DFMO during skin tumor promotion has not been reported before in the prevention of cancer in other animal models or in human cancer prevention trials...